Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed.

Related collections

Author and article information

Journal

Title: JAMA Oncology

Abbreviated Title: JAMA Oncol

Publisher: American Medical Association (AMA)

ISSN (Print): 2374-2437

Publication date (Electronic): February 13 2020

Affiliations

[1 ]The University of Chicago, Chicago, Illinois

[2 ]Mayo Clinic, Rochester, Minnesota

[3 ]University of California, San Francisco

[4 ]University of California, San Diego

[5 ]Yale University, New Haven, Connecticut

[6 ]University of Alabama, Birmingham

[7 ]Swedish Cancer Center

[8 ]Moffitt Cancer Center, Tampa, Florida

[9 ]University of Pennsylvania, Philadelphia

[10 ]Loyola University Chicago Stritch School of Medicine, Maywood, Illinois

[11 ]University of Colorado, Aurora

[12 ]Georgetown University, Washington, DC

[13 ]Oregon Health & Science University, Portland

[14 ]Quantum Leap Healthcare Collaborative, San Francisco, California

[15 ]Berry Consultants, LLC

[16 ]MD Anderson Cancer Center, Houston, Texas

[17 ]University of Minnesota, Minneapolis

[18 ]Gemini Group, Ann Arbor, Michigan

Article

DOI: 10.1001/jamaoncol.2019.6650

PMC ID: 7058271

PubMed ID: 32053137

SO-VID: 47c5f25b-f00e-4283-ac8d-872c259e724d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 242

See all cited by

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer : An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Read this article at